Palbociclib has been reported to exert its antitumor effects by inhibiting CDK4/6 [14], which is significant owing to evidence showing that the mechanism for neutropenia development may differ from that due to cytotoxic chemotherapy. This evidence concerns the gene CDK4 and Decreased total neutrophil count.